Study for the effects of semaglutid on glycemic control and quality of life in patients with type 2 diabetes
Phase 4
- Conditions
- type 2 diabetesD003924
- Registration Number
- JPRN-jRCT1011200008
- Lead Sponsor
- omoto Hiroshi
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
1) HbA1c 6.0-10.0%
2) BMI >= 22 kg/m2
3) patients who were treated with liraglutide or dulaglutide at least for 12 weeks
4) written informed consent
Exclusion Criteria
1) patients with type 2 diabetes who were treated with GLP-1 receptor agonist other than liraglutide or dulaglutide, 2) history of anaphylaxis of semaglutide, 3) unstable retinopathy, 4) severe hepatic dysfunction or renal dysfunction, 5) severe ketosis, diabetic coma, 6) severe infection, surgery, serious trauma, 7) pregnancy,8) patients who are inadequate to enter this study due to the other reasons by physician's judgments
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The change in HbA1c at 24 weeks from baseline
- Secondary Outcome Measures
Name Time Method 1) The change in QOL scores, 2) adverse effects, 3) The change in weight, abdominal circumference, blood pressure and pulse 4) The change in the other blood and urinary tests, 5) The factors associated with improvement of HbA1c and secondary endopoints, 6) Comparison of variation in each group when semaglutide shows surperiority over conventional GLP-1 receptor agonists both in plan A and B